RESPOND is the largest coordinated study on biological and non-biological factors associated with aggressive prostate cancer in African-American men. The study is an effort to learn why these men disproportionally experience aggressive disease.
NCI and the Department of Veterans Affairs (VA) are launching the NAVIGATE program at 12 VA facilities across the country to make it easier for veterans to participate in NCI-sponsored clinical trials.
A novel approach to immunotherapy developed by NCI researchers has led to the complete regression of breast cancer in a patient who was unresponsive to all other treatments. The findings were published in Nature Medicine.
A fact sheet that provides an overview of how the immune system functions and describes the actions of biological therapies, such as monoclonal antibodies, cytokines, therapeutic vaccines, the bacterium bacillus Calmet-Guérin, cancer-killing viruses, gene therapy, and adoptive T-cell transfer.